AlloVir Inc. (ALVR)
Company Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases.
The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.
The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019.
Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
| Country | United States |
| IPO Date | Jul 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Vikas Sinha CPA, |
Contact Details
Address: 1100 Winter Street Waltham, Massachusetts United States | |
| Website | https://www.allovir.com |
Stock Details
| Ticker Symbol | ALVR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001754068 |
| CUSIP Number | 019818103 |
| ISIN Number | US0198181036 |
| Employer ID | 83-1971007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Vikas Sinha C.A., CPA, M.B.A. | Chief Executive Officer, President, Chief Financial Officer & Director |
| Brett R. Hagen | Chief Accounting Officer |
| David L. Hallal | Executive Chairman of the Board |
| Dr. Ann M. Leen Ph.D. | Chief Scientific Officer |
| Edward Miller J.D. | General Counsel & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 01, 2025 | ARS | Filing |
| Jul 01, 2025 | DEFA14A | Filing |
| Jul 01, 2025 | DEF 14A | Filing |
| Jun 20, 2025 | 8-K | Current Report |
| Jun 04, 2025 | S-8 | Filing |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| Apr 16, 2025 | 8-K | Current Report |
| Apr 11, 2025 | 4 | Filing |